Shots:
- Nurix has enrolled the first patient in the global P-III (DAYBreak CLL-306) study assessing bexobrutideg in pts with r/r chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received a covalent BTK inhibitor
- The trial, conducted under the collaboration between Nurix and Roche, is expected to enroll ~620 pts, where they will be randomized to receive either bexobrutideg (600mg, PO, QD) or pirtobrutinib
- Bexobrutideg is also being evaluated as monotx. in the P-II (DAYBreak CLL-201) trial in r/r CLL and P-Ia/Ib (NX-5948-301) trial in r/r B-cell malignancies, plus in combination in P-I/II (NX-5948-203) trial for r/r and treatment naïve CLL
Ref: Globenewswire | Image: Nurix Therapeutics | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
